Jubereq (Denosumab-desu)

Jubereq (denosumab-desu) is a RANK ligand (RANKL) inhibitor indicated for:

• Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
• Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
• Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

Recommended Dosage:
Jubereq is intended for the subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally.

• Multiple Myeloma and Bone Metastasis from Solid Tumors: The recommended dose of Jubereq is 120 mg administered as a subcutaneous injection every 4 weeks in the upper arm, upper thigh, or abdomen. Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia.
• Giant Cell Tumor of Bone: The recommended dose of Jubereq is 120 mg administered every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen. Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia.
• Hypercalcemia of Malignancy: The recommended dose of Jubereq is 120 mg administered every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen.

• Patients receiving treatment with Jubereq should not receive other denosumab products at the same time. Using multiple products with the same active ingredient can increase the risk of side effects such as low calcium levels and serious bone-related complications.
• Serious allergic reactions may occur with Jubereq. Monitor patients for symptoms such as dizziness, rash, itching, facial or throat swelling, or difficulty breathing. If a hypersensitivity reaction occurs, stop treatment and provide appropriate medical care.
• This medicine can decrease blood calcium levels. Check calcium levels before starting treatment and monitor during therapy. Patients with kidney complications are at greater risk. Symptoms like tingling, muscle cramps, or confusion should be reported and treated promptly.
• Osteonecrosis of the jaw may develop with denosumab treatment. Maintain good oral hygiene and complete dental check-ups before starting treatment. Avoid invasive dental procedures if possible and report any jaw pain, swelling, or exposed bone quickly.
• Patients may experience unusual thigh or groin pain during treatment, which could indicate an atypical femur fracture. Evaluate symptoms promptly and stop treatment if a fracture is suspected. Provide appropriate orthopedic care to prevent serious complications.
• Stopping this treatment may increase the risk of multiple vertebral fractures. Evaluate patient risk before stopping and consider alternative therapy to maintain bone strength. Monitor patients closely for new back pain or fractures after discontinuing treatment.
• Jubereq may be responsible for causing harm to an unborn baby. Do not use it during pregnancy. Women of childbearing age should use effective contraception during treatment and inform their clinician immediately in case they become pregnant during therapy.
• It is not known whether this therapeutic drug passes into human breast milk. Because of potential risk to the infant, avoid breastfeeding during treatment and for some time after the final dose. Consult a healthcare professional before breastfeeding.

What documents are required to import JUBEREQ to India?

JUBEREQ (denosumab-desu) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is JUBEREQ available in India?

JUBEREQ (denosumab-desu injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Jubereq in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  Jubereq price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

JUBEREQ can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, as well as other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of JUBEREQ (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please WhatsApp +91 98104 69557 | Toll-Free Number: 1800-1200-365 or write us at info@indianpharmanetwork.in for the Jubereq cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source JUBEREQ (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Jubereq®?

Denosumab-desu is the Generic Name for the trade name drug Jubereq®.

What is the Manufacturer’s Name of Jubereq®?

Jubereq® is manufactured by Accord BioPharma Inc.

Is Jubereq approved by the FDA?

Yes. Jubereq is approved by the FDA. Date of first approval: October 29, 2025.

What is the dosage and form of Jubereq® supplied?

Jubereq is supplied for Injection: 120 mg/1.7 mL (70 mg/mL) solution in a single-dose vial for subcutaneous (SC) use.

What are the most common side effects of Jubereq® injection?

The most commonly reported side effects of Jubereq® in patients with

• Bone Metastasis from Solid Tumors: hypophosphatemia, fatigue/asthenia, and nausea.
• Multiple Myeloma: rash, diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, and headache.
• Giant Cell Tumor of Bone: arthralgia, back pain, headache, nausea, fatigue, and pain in the extremity.
• Hypercalcemia of Malignancy: nausea, headache, dyspnea, decreased appetite, constipation, peripheral edema, vomiting, anemia, and diarrhea.

How does Jubereq Import in India work?

Jubereq Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

Who is a reliable Jubereq supplier in India?

Indian Pharma Network is a trusted Jubereq supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.

How much does Jubereq® injection cost in India?

Jubereq® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Jubereq prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Jubereq cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Jubereq® injection be available in SAARC countries?

Apart from Gulf countries, Jubereq® injection can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Jubereq® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Jubereq® injection online in India?

Yes, one can buy Jubereq in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Jubereq® injection through legal channels.

Who is an authorized Jubereq importer in India?

Indian Pharma Network acts as a Jubereq importer in India, assisting with Named Patient import processes, regulatory documentation, and compliant international procurement for patients requiring this therapy.

What are the storage conditions of Jubereq® injection?

Store Jubereq refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Protect it from direct light and heat. Avoid vigorous shaking of vials.